deepull — Series C · €50M

Barcelona-based medtech deepull closed an oversubscribed €50 million Series C co-led by Columbus Venture Partners, Panakès Partners and Mérieux Equity Partners to fund clinical validation and regulatory approval of UllCORE, its automated system for detecting sepsis-causing pathogens directly from blood in about one hour. UllCORE received FDA Breakthrough Device Designation in December 2024; because three funds co-led, no single lead investor is reported.